0H8I Stock Overview
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the Americas, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region.
Notes are coming soon
Accuray Incorporated Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.43|
|52 Week High||US$4.13|
|52 Week Low||US$1.85|
|1 Month Change||24.56%|
|3 Month Change||n/a|
|1 Year Change||-40.66%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-56.99%|
Recent News & Updates
|0H8I||GB Medical Equipment||GB Market|
Return vs Industry: 0H8I underperformed the UK Medical Equipment industry which returned -9.4% over the past year.
Return vs Market: 0H8I underperformed the UK Market which returned -6.3% over the past year.
|0H8I Average Weekly Movement||n/a|
|Medical Equipment Industry Average Movement||7.6%|
|Market Average Movement||5.1%|
|10% most volatile stocks in GB Market||10.8%|
|10% least volatile stocks in GB Market||2.6%|
Stable Share Price: Insufficient data to determine 0H8I's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine 0H8I's volatility change over the past year.
About the Company
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the Americas, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy System, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day.
Accuray Incorporated Fundamentals Summary
|0H8I fundamental statistics|
Is 0H8I overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|0H8I income statement (TTM)|
|Cost of Revenue||US$263.93m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Feb 01, 2023
|Earnings per share (EPS)||-0.10|
|Net Profit Margin||-2.33%|
How did 0H8I perform over the long term?See historical performance and comparison